Bendamustine in non-Hodgkin lymphoma: The double-agent that came from the cold war

Clinical Lymphoma and Myeloma

Volumn 8, Issue SUPPL. 1, 2007, Pages

  Forero Torres, Andres ^a   Saleh, Mansoor N ^b,c  

^a University of Alabama at Birmingham   (United States)

^b UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^c NONE   (United States)

Author keywords

Alkylating agents; Follicular lymphoma; Mantle cell lymphoma; Rituximab

Indexed keywords

BENDAMUSTINE; CYCLOPHOSPHAMIDE; FLUDARABINE; MITOXANTRONE; PREDNISONE; RITUXIMAB; VINCRISTINE; CHLORAMBUCIL; INTERFERON; MELPHALAN; METHOTREXATE;

ALLERGIC REACTION; ANTINEOPLASTIC ACTIVITY; BONE MARROW SUPPRESSION; CANCER REGRESSION; CANCER RELAPSE; CANCER STAGING; CANCER SURVIVAL; CLINICAL TRIAL; GASTROINTESTINAL DISEASE; GERMAN DEMOCRATIC REPUBLIC; HUMAN; MONOTHERAPY; NONHODGKIN LYMPHOMA; PROGNOSIS; REVIEW; STATISTICAL ANALYSIS; TREATMENT RESPONSE; ADD ON THERAPY; ADVANCED CANCER; ALOPECIA; ANEMIA; AUTOLOGOUS STEM CELL TRANSPLANTATION; B CELL LYMPHOMA; BLOOD TOXICITY; CANCER COMBINATION CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER RADIOTHERAPY; CONTINUOUS INFUSION; DIARRHEA; DOSE RESPONSE; DRUG EFFICACY; DRUG FATALITY; DRUG HYPERSENSITIVITY; DRUG SAFETY; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; FATIGUE; FEBRILE NEUTROPENIA; FOLLICULAR LYMPHOMA; GASTROINTESTINAL SYMPTOM; LEUKOPENIA; LYMPHOPLASMOCYTIC LYMPHOMA; MAINTENANCE THERAPY; MANTLE CELL LYMPHOMA; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; NODAL MARGINAL ZONE LYMPHOMA; RECOMMENDED DRUG DOSE; T CELL LYMPHOMA; THROMBOCYTOPENIA; UNSPECIFIED SIDE EFFECT; VOMITING;

EID: 38849098573     PISSN: 15579190     EISSN: None     Source Type: Journal    
DOI: 10.3816/CLM.2007.s.028     Document Type: Article

References (36)

1. Barman Balfour JA, Goa KL. Bendamustine. Drugs 2001; 61:631-40.
2. Chow KU, Boehrer S, Geduldig K, et al. In vitro induction of apoptosis of neoplastic cells in low-grade non-Hodgkin's lymphoma using combinations of established cytotoxic drugs with bendamustine. Haematologica 2001; 86:485-93.
3. Herold M, Schulze A, Mantovani L, et al. BOP versus COP in advanced low-grade non-Hodgkin's lymphoma - results of a randomized multicenter study. Blood 1999; 94:262a (Abstract 220).
4. Poenisch W, Mitrou PS, Merkle KH, et al. Bendamustine/prednisone versus melphalan/prednisone in the primary treatment of multiple myeloma: an updated analysis of the 94BP01 protocol. Blood 2000; 96:759a (Abstract 3284).
5. Höffken K, Merkle K, Schönfelder M, et al. Bendamustine as salvage treatment in patients with advanced progressive breast cancer: a phase II study. J Cancer Res Clin Oncol 1998; 124:627-32.
6. Kollmannsberger C, Gerl A, Schleucher N, et al. Phase II study of bendamustine in patients with relapsed or cisplatin-refractory germ cell cancer. Anticancer Drugs 2000; 11:535-9.
7. Aivado M, Schulte K, Henze L, et al. Bendamustine in the treatment of chronic lymphocytic leukemia: results and future perspectives. Semin Oncol 2002; 29:19-22.
8. Schmittel A, Knödler M, Hortig P, et al. Phase II trial of second-line bendamustine chemotherapy in relapsed small cell lung cancer patients. Lung Cancer 2007; 55:109-13.
9. Borchmann P, Schnell R, Diehl V, et al. New drugs in the treatment of Hodgkin's disease. Ann Oncol 1998; 9:103-8.
10. Schnabel R, Jungstand W, Gutsche W, et al. Comparative studies on the cytostatic activity of the new nitrogen mustard derivate IMET 3393 and endoxan in three experimental mouse tumors (Ehrlich-ascites-carcinoma, sarcoma 180 solid, leukemia LAJ I) [in German]. Acta Biol Med German 1967; 19:534-58.
11. Hartmann M, Zimmer CH. Investigation of cross-link formation in DNA by the alkylating cytostatica IMET 3106, 3393, and 3943. Biochim Biophys Acta 1972; 287:386-9.
12. Heider A, Niederle N. Efficacy and toxicity of bendamustine in patients with relapsed low-grade non-Hodgkin's lymphomas. Anticancer Drugs 2001; 12:725-9.
13. Bremer K. Bendamustine: effective salvage chemotherapy in pretreated low-grade non-Hodgkin's lymphoma. Ann Oncol 1999; 10:127 (Abstract 458).
14. Forero-Torres A, Cohen P, Cheson BD, et al. A phase II study of single-agent bendamustine in rituximab-refractory B-Cell non-Hodgkin's lymphoma. Ann Oncol 2006; 17(19 suppl):ix203 (Abstract 669P).
15. Friedberg JW, Cohen P, Chen L, et al. Bendamustine in patients with rituximab-refractory indolent and transformed non-Hodgkin's lymphoma: results from a phase II multicenter, single-agent study. J Clin Oncol 2008. In press.
16. Cephalon announces positive results from its pivotal study of Treanda in patients with non-Hodgkin's lymphoma [press release]. Frazer, PA: Cephalon; October 23, 2007.
17. Weidmann E, Kim SZ, Rost A, et al. Bendamustine is effective in relapsed or refractory aggressive non-Hodgkin's lymphoma. Ann Oncol 2002; 13:1285-9.
18. Ruffert K, Jann H, Syrbe G, et al. Cytostasan (bendamustine) as an alternative therapeutic approach to treat malignant non-Hodgkin's lymphoma [in German]. Z Klin Med 1989; 44:671-4.
19. Brockmann B. Therapy for the recurrence of malignant lymphoma [in German]. Z Arztl Fortbild 1992; 86:843-6.
20. Blumenstengel K, Fricke HJ, Kam R, et al. Bendamustine, vincristine, prednisone in relapsed and refractory low-grade non-Hodgkin's lymphoma. Ann Hematol 1998; 77:S149.
21. Heck HK, Preiss JM, Schmidt P. Bendamustine and mitoxantrone in the treatment of low-grade non-Hodgkin's lymphoma. J Cancer Res Clin Oncol 1998; 124:R147.
22. König U, Junghass C, Decker S, et al. Response of refractory and relapsed low-grade non-Hodgkin's lymphoma and chronic lymphocytic leukemia to Dexa-BIF, a bendamustine hydrochloride-containing regimen. Ann Oncol 1999; 10:132 (Abstract 479).
23. Herold M, Schulze A, Niederwieser D, et al. Bendamustine, vincristine, and prednisone (BOP) versus cyclophosphamide, vincristine, and prednisone (COP) in advanced indolent non-Hodgkin's lymphoma and mantle cell lymphoma: results of a randomized phase III trial (OSHO# 19). J Can Res Clin Oncol 2006; 132:105-12.
24. Ruffert K. Therapy of low-grade non-Hodgkin's lymphoma with bendamustine and oral etoposide. Ann Oncol 1999; 10:125 (Abstract 452).
25. Kath R, Hoffken K, Merkle K. Prevention of immunological complications in bendamustine treatment. Onkologie 2000; 23:171 (Abstract 0649).
26. Koenigsmann M, Knauf W, Herold M, et al. Fludatabine and bendamustine in refractory and relapsed indolent lymphoma: a multicenter phase I/II trial of the East-German Society of Hematology and Oncology (OSHO). Leuk Lymphoma 2004; 45:1821-7.
27. Kalh C, Herold M, Hoffkes H, et al. Bendamustine, methotrexate, mitoxantrone and prednisone (BMMP) for the treatment of high-grade non-Hodgkin's lymphomas. Onkologie 1997; 20:406-8.
28. Wilson WH. Chemotherapy sensitization by rituximab: experimental and clinical evidence. Semin Oncol 2000; 27:30-6.
29. Chow KU, Sommerland WD, Boehrer S, et al. Anti-CD20toki antibody (IDEC-C2B8, rituximab) enhances efficacy of cytotoxic dtugs on neoplastic lymphocytes in vitro: role of cytokines, complement, and caspases. Haematologica 2002; 87:33-43.
30. Weide R, Heymanns J, Gores A, et al. Bendmustine, mitoxantrone and rituximab (BMR): a new effective treatment for refractory or relapsed indolent lymphomas. Leuk Lymphoma 2002; 43:327-31.
31. Rummel MJ, Al-Batran SE, Kim SZ, et al. Bendamustine plus rituximab is effective and has a favorable toxicity profile in the treatment of mantle cell and low-grade non-Hodgkin's lymphoma. J Clin Oncol 2005; 23:3383-9.
32. Rummel MJ, Atta M, Welslau D, et al. Bendamustine and rituximab in the treatment Bendamustine and rituximab (BR) are effective in the treatment of relapsed or refractory indolent and mantle-cell lymphomas: long-term follow-up of a phase II study. J Clin Oncol 2007; 25(18 suppl):449s (Abstract 8034).
33. Weide R, Hess G, Köppler H, et al. High anti-lymphoma activity of bendamustine/mitoxantrone/rituximab in rituximab pretreated relapsed or refractory indolent lymphomas and mantle cell lymphomas. A multicenter phase II study of the German Low Grade Lymphoma Study Group (GLSG). Leuk Lymphoma 2007; 48:1299-306.
34. Williams ME, Cohen P, Tulpule R, et al. A phase II, multicenter study of bendamustine HCl plus rituximab in relapsed indolent B-cell and mantle-cell non-Hodgkin's lymphoma. J Clin Oncol 2006; 24(18 suppl):429s (Abstract 7528).
35. Van der Jagt RH, Cohen P, Cheson BD, et al. Phase II results of bendamustine in combination with rituximab in relapsed indolent and mantle cell non-Hodgkin's lymphoma. Blood 2006; 108:766a (Abstract 2710).
36. Kirchner HH, Gaede B, Steinhauer EU, et al. Chemoimmunotherapy with fludarabine, bendamustine and rituximab for relapsed low grade malignant non-Hodgkin's lymphoma. Blood 2001; 98:135a (Abstract 568).